Can immunoglobulin (IVIG) be used in conjunction with Teflaro (ceftaroline)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 17, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Can IVIG Be Used with Teflaro (Ceftaroline)?

Yes, intravenous immunoglobulin (IVIG) can be safely used in conjunction with Teflaro (ceftaroline), as there are no known drug interactions or contraindications between these two agents.

Compatibility and Safety Profile

  • No documented interactions exist between IVIG and ceftaroline based on their distinct mechanisms of action and pharmacological properties 1.

  • Ceftaroline is a broad-spectrum cephalosporin antibiotic that works by binding to penicillin-binding proteins, with low protein binding (<20%) and primarily renal elimination 1.

  • IVIG functions through multiple immune mechanisms including Fc-γ receptor blockade, complement inhibition, B-cell receptor downregulation, and neutralization of circulating antibodies and cytokines 2.

Clinical Context for Combined Use

The combination may be clinically appropriate in several scenarios:

Severe Infections with Immune Dysfunction

  • IVIG may benefit select patients with septic shock caused by toxic shock syndrome (especially streptococcal etiology), necrotizing fasciitis, or those with primary humoral immunodeficiencies 2.

  • Ceftaroline provides broad-spectrum coverage including MRSA, making it suitable for complicated skin and soft tissue infections where IVIG might be considered as adjunctive therapy 1.

Immunocompromised Patients

  • Patients with documented hypogammaglobulinemia and recurrent infections may require IVIG replacement therapy while receiving antibiotics like ceftaroline for acute infections 2.

  • Those with secondary antibody deficiency states (multiple myeloma, chronic lymphocytic leukemia) may need both antimicrobial coverage and immunoglobulin supplementation 3, 4.

Administration Considerations

IVIG Safety Monitoring

  • Monitor for immediate adverse effects including headache, flushing, fever, chills, myalgia, blood pressure changes, and tachycardia during infusion 5.

  • Assess renal function before and during IVIG administration, particularly in high-risk patients with pre-existing renal disease, dehydration, diabetes, advanced age, or hypertension 5.

  • Use slow infusion rates of low concentration IVIG products with adequate hydration to prevent renal failure and thromboembolic complications 5.

Ceftaroline Dosing

  • Ceftaroline 600 mg IV every 12 hours is the standard dose for complicated skin and soft tissue infections 1.

  • Dosage adjustment is required for moderate renal impairment (creatinine clearance 30-50 mL/min), though no adjustment needed for mild impairment 1.

Important Caveats

  • IVIG is not routinely recommended for most infectious conditions and should be reserved for specific indications where evidence supports benefit 2.

  • The decision to use IVIG should be based on documented immunodeficiency, specific disease states (toxic shock syndrome, ANCA-associated vasculitis, immune thrombocytopenia), or refractory conditions rather than routine infection management 2.

  • Cost considerations are significant as IVIG is an expensive blood product of potentially limited supply that requires careful justification 6.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

New and controversial uses of intravenous gamma-globulin.

The Pediatric infectious disease journal, 1988

Research

Intravenous immunoglobulin: adverse effects and safe administration.

Clinical reviews in allergy & immunology, 2005

Research

Immunoglobulin therapy.

Clinical medicine (London, England), 2016

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.